Ocular Therapeutix, Inc.

NasdaqGM:OCUL Rapporto sulle azioni

Cap. di mercato: US$1.4b

Ocular Therapeutix Crescita futura

Future criteri di controllo 2/6

Si prevede che Ocular Therapeutix aumenterà gli utili e i ricavi rispettivamente del 15.5% e 43.7% all'anno, mentre si prevede che l'EPS crescerà del 17.8% all'anno.

Informazioni chiave

15.5%

Tasso di crescita degli utili

17.8%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili23.7%
Tasso di crescita dei ricavi43.7%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento20 Nov 2024

Aggiornamenti recenti sulla crescita futura

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10
Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Recent updates

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Oct 16
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

Oct 11

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10
Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

Jul 23

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Jul 15
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Jun 05
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Jun 01

Ocular Therapeutics' Impressive Surge: A Strategic Insight

Mar 19

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

Feb 11

Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD

Jan 10

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Jan 09
Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Oct 15
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Jun 30
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Mar 08
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Feb 11
Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Nov 16
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Sep 09
Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:OCUL - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202677-204-106-1736
12/31/202573-179-142-1589
12/31/202464-188-146-1339
9/30/202461-174-119-118N/A
6/30/202461-138-91-89N/A
3/31/202460-115-87-84N/A
12/31/202358-81-76-70N/A
9/30/202358-67-73-65N/A
6/30/202355-91-78-70N/A
3/31/202352-89-68-61N/A
12/31/202251-71-63-60N/A
9/30/202250-59-60-58N/A
6/30/202250-33-59-58N/A
3/31/202249-22-68-67N/A
12/31/202144-7-67-66N/A
9/30/202139-88-57-57N/A
6/30/202132-103-58-57N/A
3/31/202122-131-53-52N/A
12/31/202017-156-54-54N/A
9/30/202012-96-68-67N/A
6/30/20207-103-74-73N/A
3/31/20206-91-79-77N/A
12/31/20194-86-80-78N/A
9/30/20192-78-74-72N/A
6/30/20192-74-65-63N/A
3/31/20192-63-58-56N/A
12/31/20182-60-51-49N/A
9/30/20182-56-48-46N/A
6/30/20182-56N/A-49N/A
3/31/20182-61N/A-48N/A
12/31/20172-63N/A-50N/A
9/30/20172-63N/A-48N/A
6/30/20172-57N/A-41N/A
3/31/20172-50N/A-39N/A
12/31/20162-45N/A-34N/A
9/30/20162-43N/A-35N/A
6/30/20162-44N/A-37N/A
3/31/20162-43N/A-36N/A
12/31/20152-40N/A-34N/A
9/30/20152-37N/A-31N/A
6/30/20152-33N/A-27N/A
3/31/20151-29N/A-23N/A
12/31/20141-29N/A-20N/A
9/30/20140-24N/A-18N/A
6/30/20140-20N/A-15N/A
3/31/20140-17N/A-13N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che OCUL rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che OCUL rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che OCUL rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di OCUL ( 43.7% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di OCUL ( 43.7% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di OCUL è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita